Magenta Therapeutics Inc. (MGTA)
Magenta Therapeutics Statistics
Share Statistics
Magenta Therapeutics has 60.66M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 60.66M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 33.64M |
| Failed to Deliver (FTD) Shares | 2.08K |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.02 and the forward PE ratio is null. Magenta Therapeutics's PEG ratio is -0.01.
| PE Ratio | -0.02 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.02 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Magenta Therapeutics has an Enterprise Value (EV) of -26.43M.
| EV / Sales | 0 |
| EV / EBITDA | 0.33 |
| EV / EBIT | 0.39 |
| EV / FCF | 0.39 |
Financial Position
The company has a current ratio of 7.95, with a Debt / Equity ratio of 0.28.
| Current Ratio | 7.95 |
| Quick Ratio | 7.95 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.44 |
| Interest Coverage | 18.22 |
Financial Efficiency
Return on Equity is -67.97% and Return on Invested Capital is -56.07%.
| Return on Equity | -67.97% |
| Return on Assets | -49.11% |
| Return on Invested Capital | -56.07% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.07M |
| Employee Count | 67 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.44M |
| Effective Tax Rate | 5.81% |
Stock Price Statistics
The stock price has increased by 0.06% in the last 52 weeks. The beta is 2.11, so Magenta Therapeutics's price volatility has been higher than the market average.
| Beta | 2.11 |
| 52-Week Price Change | 0.06% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 36.83 |
| Average Volume (20 Days) | 247.98K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -80.9M |
| Net Income | -72.02M |
| EBITDA | -78.98M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -23.05 |
Balance Sheet
The company has 57.63M in cash and 29.96M in debt, giving a net cash position of 27.66M.
| Cash & Cash Equivalents | 57.63M |
| Total Debt | 29.96M |
| Net Cash | 27.66M |
| Retained Earnings | -402.03M |
| Total Assets | 192.46M |
| Working Capital | 178.37M |
Cash Flow
In the last 12 months, operating cash flow was -67.09M and capital expenditures -314K, giving a free cash flow of -67.4M.
| Operating Cash Flow | -67.09M |
| Capital Expenditures | -314K |
| Free Cash Flow | -67.4M |
| FCF Per Share | -21.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MGTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5834.95% |
| FCF Yield | -5460.82% |
Analyst Forecast
Currently there are no analyst rating for MGTA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.64 |
| Piotroski F-Score | 2 |